BEAM
Price
$27.98
Change
-$0.16 (-0.57%)
Updated
Dec 26 closing price
Capitalization
2.86B
66 days until earnings call
Intraday BUY SELL Signals
IGC
Price
$0.30
Change
-$0.00 (-0.00%)
Updated
Dec 26 closing price
Capitalization
27.85M
53 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs IGC

Header iconBEAM vs IGC Comparison
Open Charts BEAM vs IGCBanner chart's image
Beam Therapeutics
Price$27.98
Change-$0.16 (-0.57%)
Volume$1.01M
Capitalization2.86B
IGC Pharma
Price$0.30
Change-$0.00 (-0.00%)
Volume$339.62K
Capitalization27.85M
BEAM vs IGC Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. IGC commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and IGC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (BEAM: $27.98 vs. IGC: $0.30)
Brand notoriety: BEAM and IGC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 50% vs. IGC: 39%
Market capitalization -- BEAM: $2.84B vs. IGC: $27.85M
BEAM [@Biotechnology] is valued at $2.84B. IGC’s [@Biotechnology] market capitalization is $27.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileIGC’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • IGC’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than IGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while IGC’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 5 bearish.
  • IGC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than IGC.

Price Growth

BEAM (@Biotechnology) experienced а +5.31% price change this week, while IGC (@Biotechnology) price change was -0.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

IGC is expected to report earnings on Feb 18, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.86B) has a higher market cap than IGC($27.9M). BEAM YTD gains are higher at: 13.468 vs. IGC (-10.744). IGC has higher annual earnings (EBITDA): -7.52M vs. BEAM (-434.55M). BEAM has more cash in the bank: 1.08B vs. IGC (1.13M). IGC has less debt than BEAM: IGC (146K) vs BEAM (151M). BEAM has higher revenues than IGC: BEAM (55.7M) vs IGC (1.11M).
BEAMIGCBEAM / IGC
Capitalization2.86B27.9M10,237%
EBITDA-434.55M-7.52M5,776%
Gain YTD13.468-10.744-125%
P/E RatioN/AN/A-
Revenue55.7M1.11M5,036%
Total Cash1.08B1.13M95,133%
Total Debt151M146K103,425%
FUNDAMENTALS RATINGS
BEAM vs IGC: Fundamental Ratings
BEAM
IGC
OUTLOOK RATING
1..100
262
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4079
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5030

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IGC's Valuation (31) in the Biotechnology industry is in the same range as BEAM (33) in the null industry. This means that IGC’s stock grew similarly to BEAM’s over the last 12 months.

IGC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that IGC’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's SMR Rating (97) in the null industry is in the same range as IGC (98) in the Biotechnology industry. This means that BEAM’s stock grew similarly to IGC’s over the last 12 months.

BEAM's Price Growth Rating (40) in the null industry is somewhat better than the same rating for IGC (79) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than IGC’s over the last 12 months.

BEAM's P/E Growth Rating (100) in the null industry is in the same range as IGC (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to IGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMIGC
RSI
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 18 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 20 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
IGC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSCNX24.090.07
+0.29%
Loomis Sayles Small Cap Value N
FGKFX39.050.08
+0.21%
Fidelity Growth Company K6
TADCX26.140.05
+0.19%
Transamerica US Growth C
DHPIX16.33N/A
N/A
Diamond Hill Mid Cap I
DNLAX47.44-0.10
-0.21%
BNY Mellon Natural Resources A

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.33%
CRSP - BEAM
71%
Closely correlated
+0.44%
RXRX - BEAM
61%
Loosely correlated
+0.92%
NTLA - BEAM
61%
Loosely correlated
+1.80%
PRME - BEAM
59%
Loosely correlated
-3.25%
AXON - BEAM
57%
Loosely correlated
+0.02%
More

IGC and

Correlation & Price change

A.I.dvisor indicates that over the last year, IGC has been loosely correlated with TECX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if IGC jumps, then TECX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGC
1D Price
Change %
IGC100%
-1.09%
TECX - IGC
49%
Loosely correlated
-4.22%
ANVS - IGC
30%
Poorly correlated
-1.64%
CRBU - IGC
30%
Poorly correlated
-1.16%
ARTL - IGC
29%
Poorly correlated
-5.70%
BEAM - IGC
29%
Poorly correlated
-0.57%
More